Redefining the role of thiazolidinediones in the management of type 2 diabetes

Figures & data

Figure 1 Kaplan–Meier curves showing the proportion of patients in pioglitazone and gliclazide treatment groups not failing (HbA_1c <8.0%) at various time points over 2 years. Copyright © 2005 American Diabetes Association. From Diabetes Care^®, Vol. 28, 2005;544–550. Reprinted with permission from The American Diabetes Association.

Table 1 In the study of Goldberg et al a total of 802 subjects were randomized to blinded treatment with maximal dose of either pioglitazone or rosiglitazone to determine the effect of these agents on fasting lipids in the setting of no other glucose or lipid-lowering therapy. The observed changes in lipid concentrations from baseline are shown⁷³

Outcome measure	Pioglitazone (n = 363)	Rosiglitazone (n = 356)
Triglycerides, mmol/L	−0.59 ± 0.09	0.15 ± 0.09
HDL-C, mmol/L	0.13 ± 0.01	0.06 ± 0.01
Non-HDL, mmol/L	0.09 ± 0.05	0.67 ± 0.05
LDL, mmol/L	0.32 ± 0.04	0.55 ± 0.04
TC, mmol/L	0.23 ± 0.05	0.73 ± 0.05
TC-to-HDL ratio	−0.3 ± 0.1	0.7 ± 0.1
Apolipoprotein B, g/L	0.00 ± 0.01	0.11 ± 0.01

Notes: Data are means ± SE; p < 0.001 for all outcomes measures listed here.

Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

Figure 2 In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride. Developed from data of Nissen et al 2008.⁸³

Abbreviation: PAV, percent atheroma volume.

GoldbergRBKendallDMDeegMAA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaDiabetes Care2005281547155415983299

 PubMed Web of Science ®Google Scholar

NissenSENichollsSJWolskiKComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialJAMA20082991561157318378631

 PubMed Web of Science ®Google Scholar